» Articles » PMID: 35898683

Outcome Prediction of Hematologic Malignancy in Critically Sick People

Abstract

People with hematologic malignancies (HM) frequently postulate intensive care unit (ICU) hospitalization due to organ damage caused by the disease process or treatment-related consequences. This study is aimed at looking at mortality and sign factors in adult patients with hematologic malignancy (HM) who have been hospitalized in the ICU. Death was one quality indicator; researchers used a machine learning approach to find determinants of death. As per the study, there have been 206 patients hospitalized in the ICU (mean age: 51.3 ± 13.6 years; 60% male). The average length of stay was three days, with 14.1% requiring extended ICU commitment. ICU death was 45.6% at 30 days, 62.6% at sixty days, and 74.3% at twelve months, rising to 59.2% at thirty days, 62.6% at sixty days, and 74.3% at twelve months. Ventilation systems and vasodilating medication were linked to higher ICU death, but admission to the ICU surgically and experiencing malignancies are linked with lower death rates. Patients with HM who are hospitalized in the ICU have a high mortality rate (45.6%), which rises to 74.3% after a year. Serious illness, postsurgical hospitalization, and malignancy were revealed as determinants of patient outcomes in multivariate analyses.

Citing Articles

Characteristics and outcomes of cancer patients admitted to intensive care units in cancer specialized hospitals in China.

Liu W, Zhou D, Zhang L, Huang M, Quan R, Xia R J Cancer Res Clin Oncol. 2024; 150(4):205.

PMID: 38642154 PMC: 11032264. DOI: 10.1007/s00432-024-05727-0.


Retracted: Outcome Prediction of Hematologic Malignancy in Critically Sick People.

International B Biomed Res Int. 2024; 2023:9765356.

PMID: 38188766 PMC: 10769595. DOI: 10.1155/2023/9765356.

References
1.
Gristina G, Antonelli M, Conti G, Ciarlone A, Rogante S, Rossi C . Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observational survey. Crit Care Med. 2011; 39(10):2232-9. DOI: 10.1097/CCM.0b013e3182227a27. View

2.
Lamoth F, Kontoyiannis D . Therapeutic Challenges of Non- Invasive Mold Infections in Immunosuppressed Patients. Antimicrob Agents Chemother. 2019; 63(11). PMC: 6811444. DOI: 10.1128/AAC.01244-19. View

3.
Stanzani M, Lewis R, Fiacchini M, Ricci P, Tumietto F, Viale P . A risk prediction score for invasive mold disease in patients with hematological malignancies. PLoS One. 2013; 8(9):e75531. PMC: 3784450. DOI: 10.1371/journal.pone.0075531. View

4.
Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J . Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol. 2013; 31(22):2810-8. DOI: 10.1200/JCO.2012.47.2365. View

5.
Lanore J, Brunet F, Pochard F, Bellivier F, Dhainaut J, Vaxelaire J . Hemodialysis for acute renal failure in patients with hematologic malignancies. Crit Care Med. 1991; 19(3):346-51. DOI: 10.1097/00003246-199103000-00011. View